

**Pegylated interferon alfa-2a (Pegasys[®])
Roche**

(No. 10/02)

Summary of Recommendation

6 September 2002

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

ADVICE

Recommended for restricted use within NHS Scotland.

REASONS FOR ADVICE

Pegylated interferon alfa-2a is an appropriate treatment for the treatment of adult patients with chronic hepatitis C under the overall supervision of specialists experienced in the management of this disorder. This treatment involves a weekly injection from a pre-filled syringe that reduces inconvenience to patients whilst increasing the response rate over interferon alfa-2a alone or in combination with Ribavirin.

Professor David H Lawson
Chairman